CHCWM – Cancer & Hematology Centers of West Michigan

NGM707 (NGM Biopharmaceuticals)

Description:  A Phase 1 / 2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Mechanism of Action:  anti-ILT2/ILT4 monoclonal antibody (activates myeloid cells).

Target Patient Population:   Most Solid Tumors

Study Design:  Drug is given IV every 3 weeks